QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 reported-saturday-nucana-highlights-synergy-between-nuc-7738-and-pd-1-inhibitors-in-rcc-organoids-supporting-expansion-of-nutide701-clinical-study

NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell DeathData Reinforces Mechanism of Action along with Efficacy an...

 nucana-publishes-nutide303-clinical-and-preclinical-data-on-nuc-3373-in-medrxiv-and-plos-one

NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated PatientsLatest Data ...

 nucana-cancels-all-remaining-series-a-warrants-after-raising-required-capital-eliminating-overhang-from-may-2025-offering

NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announces it has successfully canceled all remaining Serie...

 nucana-announces-1-for-200-ads-ratio-change-effective-august-8-2025

NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced plans to change the ratio of its American Deposi...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION